China's medical products administrator approved APT Medical (SHA:688617) subsidiary Shenzhen Huitai Medical Device's registration for its disposable magnetoelectric positioning pressure monitoring pulse electric field ablation catheter, according to a Thursday filing with the Shanghai bourse.
The device is intended for the treatment of drug-refractory, recurrent, and symptomatic paroxysmal atrial fibrillation or abnormal electric impulses in the heart.
The device is used with the cardiac pulse electric field ablation device produced by Shanghai Hongtong Industrial.
Shares fell 1% during Thursday's trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。